dactinomycin has been researched along with ethamolin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gunji, Y; Kanai, N; Kashii, Y; Momoi, MY; Odaka, J; Saito, M; Yamauchi, T | 1 |
1 review(s) available for dactinomycin and ethamolin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for dactinomycin and ethamolin
| Article | Year |
|---|---|
Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Guanidines; Hemangioendothelioma; Humans; Immunohistochemistry; Infant; Interferon-alpha; Magnetic Resonance Imaging; Male; Oleic Acids; Platelet Transfusion; Prednisolone; Prognosis; Sclerosing Solutions; Sclerotherapy; Soft Tissue Neoplasms; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vincristine | 2009 |